期刊档案 · Medicine-Immunology and Allergy
Antibody Therapeutics
ISSN 2516-4236 · Oxford University Press · United Kingdom
Antibody Therapeutics 中科院新锐版 医学 3区,影响因子 56(官网公布),完全开放获取,APC 约 2,687 美元,近 24 个月 73 篇文章投稿到接收中位 103 天,2025 年发文 28 篇,ESCI、Scopus 收录。
研究范围
研究范围与定位
Antibody Therapeutics 由 Oxford University Press 出版,属中科院医学大类。按 OpenAlex 近年发文统计,该刊主要发表 Monoclonal and Polyclonal Antibodies Research、CAR-T cell therapy research、Protein purification and stability 等主题的论文,这 3 个主题约占 47.1%,主导子领域为 Molecular Biology。(根据 OpenAlex 主题统计与中科院分区数据生成)
A peer-reviewed, online, open access journal, Antibody Therapeutics provides a forum for the publication of the latest advances and challenges in the discovery, research, development, manufacturing, and methodology of therapeutic antibodies for the global scientific community. Topics include target and antibody discovery, mechanistic research, new technologies and methods, manufacturing, clinical trials, regulation, policies, and more. Antibody Therapeutics article types include original research, reviews, cutting-edge technologies, new methods, news, interviews, and meeting highlights. Journal metrics Citation metrics Clarivate 2025 Impact Factor 4.8 Scopus 2025 CiteScore 7.8 Immunology And Allergy (Rank by CiteScore) 57/234 Immunology (Rank by CiteScore) 62/243 2025 Source Normalized Impact per Paper (SNIP) 1.092 Readership 2025 Full Text Usage 207,842 Peer Review and Production 2025 Median days from submission to first decision 30 days 2025 Median days from submission to final decision 66 days About metrics Disclaimer Statements of fact and opinion in the articles in Antibody Therapeutics are those of the respective authors and contributors and not of the Journal, ChAbS, or Oxford University Press, unless otherwise expressly indicated. Neither Oxford University Press, ChAbS, nor the Journal make any representation, express or implied, in respect of the accuracy of the material in the Journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. Readers should make their own evaluation as to the appropriateness or otherwise of the information included.
摘自期刊官网 Aims & Scope
研究方向(LetPub):Medicine-Immunology and Allergy
主编 Mitchell Ho出版商官网
编委会国家分布:中国大陆 17 位(约 46%);主要国家 中国 17、美国 16、英国 1、韩国 1、德国 1(共 37 位编委标注了国家) 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计,占比为近似值
- Monoclonal and Polyclonal Antibodies ResearchMedicine30.8%
- CAR-T cell therapy researchMedicine9%
- Protein purification and stabilityBiochemistry, Genetics and Molecular Biology7.3%
- HER2/EGFR in Cancer ResearchMedicine7%
- SARS-CoV-2 and COVID-19 ResearchMedicine5%
- Glycosylation and Glycoproteins ResearchBiochemistry, Genetics and Molecular Biology4%
- Immunotherapy and Immune ResponsesImmunology and Microbiology3.8%
- Viral Infectious Diseases and Gene Expression in InsectsBiochemistry, Genetics and Molecular Biology3.7%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表( 2025年3月升级版)未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》( 2026年3月发布)医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 免疫学IMMUNOLOGY | 3 区 |
Top 期刊:否综述期刊:未标注
期刊分区表( 2023年12月旧的升级版)未收录
该期刊未被此版本分区表收录。
数据库收录
ESCIScopusDOAJLetPub
国际期刊预警名单:各版本均未列入LetPub
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子(出版商公布) 2025
- 56出版商官网 ·
- CiteScore 2026-06
- 7.8LetPub ·
- CiteScore(出版商公布) 2025
- 7.8出版商官网 ·
- SJR 2026-06
- 1LetPub ·
- SNIP 2026-06
- 1.09LetPub ·
- h-index
- 34OpenAlex ·
- i10-index
- 88OpenAlex ·
- 两年平均被引
- 3.23OpenAlex ·
- 自引率
- 4.2%LetPub ·
- Gold OA 文章占比
- 100%LetPub ·
发文规模
- 年文章数
- 27LetPub ·
- 年下载量(出版商公布)
- 2,025出版商官网 ·
- 年下载量(出版商公布) 2025
- 207,842出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 297 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 48 | 48 | 6 |
| 2025 | 28 | 28 | 163 |
| 2024 | 34 | 34 | 186 |
| 2023 | 57 | 57 | 365 |
| 2022 | 34 | 34 | 696 |
| 2021 | 28 | 28 | 711 |
不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
103 天投稿到接收中位数 · P25–P75 69 天 – 134 天
- 接收到上线
- 中位数 11 天(74 篇)
- 投稿到上线
- 中位数 113 天
- 样本
- 73 篇有投稿与接收日期的文章(窗口内共 78 篇),最近一篇接收于
只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度(社区反馈)
- 8 WeeksLetPub ·
- 投稿到首次决定 2025
- 30 天出版商官网 ·
- 投稿到最终决定 2025
- 66 天出版商官网 ·
- 投稿到发表(期刊自报)
- 约 8 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
所有文章开放获取,通常向作者收取文章处理费(APC)。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 2,687 | 有 | CC BY、CC BY-NC | |
| OpenAlex | USD 2,822 | — | — | |
| LetPub | USD 2,687 | 有 | — | |
| 出版商官网 | USD 3,625 | — | — |
其他费用与减免(作者指南)
- 版面费
- USD 3,625
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。
投稿要求
文章类型与投稿政策(官网)
投稿准备要点5 项,摘自作者指南
- 摘要
- ≤ 250 词
- 关键词
- ≥ 3 个
- 正文篇幅
- ≤ 5,000 词
- 参考文献格式
- 顺序编码制(按引用顺序编号)
- 首次投稿格式
- 允许不按期刊格式排版(free format)
接收的文章类型8 种,含篇幅限制
- brief reportResearch articles: Report the original laboratory or clinical research within the journal’s scope of interests. Method and technology development papers includi…正文 ≤ 2,000 词 · 摘要 ≤ 150 词
- editorialThese papers are normally written by the Editor-in-Chief or an editorial board member invited by the Editor-in-Chief. They normally discuss research paper(s) pu…正文 ≤ 3,000 词 · 摘要 ≤ 150 词
- mini reviewThe same topics and formatting as a review, but with a focused message. Format Guide: Word limit: 3,000 words Statement of Significance: Key points should be su…正文 ≤ 3,000 词 · 摘要 ≤ 150 词
- original researchResearch articles: Report the original laboratory or clinical research within the journal’s scope of interests. Method and technology development papers includi…未说明篇幅
- perspectiveResearch articles: Report the original laboratory or clinical research within the journal’s scope of interests. Method and technology development papers includi…未说明篇幅
- research articleResearch articles: Report the original laboratory or clinical research within the journal’s scope of interests. Method and technology development papers includi…未说明篇幅
- reviewResearch articles: Report the original laboratory or clinical research within the journal’s scope of interests. Method and technology development papers includi…正文 ≤ 5,000 词 · 摘要 ≤ 250 词
- reviewsABT will publish scholarly, comprehensive reviews that summarize and critically evaluate research in the field, addressing and identifying future implications.未说明篇幅
官网政策摘录作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、预印本、自存档
- 作者资格 Authorship
作者身份仅限于对所描述工作的设计和执行做出重大贡献的人。参与未达到作者标准的贡献者应被致谢,但不应被列为作者。该期刊不允许幽灵作者身份,也不允许客座/礼品作者身份。 模型中文摘要
Authorship is confined to those who have made a significant contribution to the design and execution of the work described. Any contributors whose participation does not meet the criteria for authorship should be acknowledged but not listed as an author. For a detailed definition of authorship, please see the International Committee of Medical Journal Editors (ICMJE) definitions of authors and con…
原文 ↗出版商官网 ·- 利益冲突 Disclosure of potential conflicts of interest
期刊要求所有作者在提交时披露任何潜在的利益冲突。通讯作者有责任确保所有作者的利益冲突向期刊声明。作者必须在提交的稿件中致谢之后包含利益冲突声明。 模型中文摘要
Authors The Journal requires all authors to disclose any potential conflict of interest at the point of submission. It is the responsibility of the corresponding author to ensure that conflicts of interest of all authors are declared to the Journal. Authors must do this by including a conflict-of-interest statement after the acknowledgements in your submitted manuscript. Authors with commercial or…
原文 ↗出版商官网 ·- 数据可用性 Availability of data and materials
在伦理可行的情况下,强烈鼓励作者向读者提供论文结论所依赖的所有数据和软件代码。作者必须在文章中包含数据可用性声明。 模型中文摘要
Where ethically feasible, Antibody Therapeutics strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. Authors are required to include a Data Availability Statement in their article. We suggest that data be presented in the main manuscript or additional supporting files, or deposited in a public repository whenever possible. …
原文 ↗出版商官网 ·- 出版伦理 Misconduct
作者应遵守研究诚信和出版伦理的高标准。数据伪造或捏造(包括不当的图像处理)、剽窃(包括未经适当引用而重复发表作者自己的作品)以及盗用他人作品都是不可接受的行为。 模型中文摘要
Authors should observe high standards with respect to research integrity and publication ethics as set out by the Committee on Publication Ethics (COPE). Falsification or fabrication of data including inappropriate image manipulation, plagiarism, including duplicate publication of the author's own work without proper citation, and misappropriation of work are all unacceptable practices. Allegation…
原文 ↗出版商官网 ·- 许可与版权
作者必须为稿件中使用的任何非本人持有版权的材料(包括引用、表格、插图或图像)获得许可。 模型中文摘要
As an author, you must obtain permission for any material used within your manuscript for which you are not the rightsholder, including quotations, tables, figures, or images.
原文 ↗出版商官网 ·- 开放获取 Open access charge
书评费用为 3625 美元,学会会员折扣为 20%。所有声明的费用均不含任何适用的增值税、商品及服务税及任何类似的销售税或消费税。 模型中文摘要
Book review charge 3625 USD Society membership discount 20% Total 0 USD Charges are quoted based on the information provided. The Low and Middle Income Countries discount is applied prior to any other discount. Please note that these prices are subject to change. All stated charges are exclusive of any applicable value added tax, goods and services tax and any similar sales or excise taxes (Sales …
原文 ↗出版商官网 ·- 同行评审 Peer Review
该期刊采用单盲同行评审,即编辑和审稿人知道作者的身份,但审稿人的身份仅编辑知晓,对作者隐藏。 模型中文摘要
Antibody Therapeutics conducts rigorous and constructive single-anonymized peer review, meaning that the identity of the authors is known to the editors and to the reviewers, but that the reviewers’ identities are known only to the editors and are hidden from the authors. All submissions to the journal are initially reviewed by one of the Editors. At this stage manuscripts may be rejected without …
原文 ↗出版商官网 ·- 预印本 Preprints
作者保留通过多种渠道提供作者原始版本(预印本)的权利,这不妨碍向期刊投稿。如果被接受,作者需要更新任何预印本的状态,包括添加已发表论文的 DOI。 模型中文摘要
As an author, you retain the right to make an Author’s Original Version (preprint) available through various channels and this does not prevent submission to the Journal. If accepted, the authors are required to update the status of any preprint, including adding your published paper’s DOI. For full details on allowed channels and updating your preprint, please see our Author self-archiving policy…
原文 ↗出版商官网 ·- 自存档 Self-archiving
自存档指将作品副本发布在公开可访问的网站或存储库上。在某些情况下,可以在自己的网页、机构网页和其他存储库中自存档作品版本。 模型中文摘要
Self-archiving refers to posting a copy of your work on a publicly accessible website or repository. Under certain circumstances, you may self-archive versions of your work on your own webpages, on institutional webpages, and in other repositories. For information about the Journal's policy, and to learn which version(s) of your paper are acceptable for self-archiving, please see our Author self-a…
原文 ↗出版商官网 ·
摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Oxford University Press
- 出版国家或地区
- United Kingdom
- 出版语言
- English
- ISSN
- 2516-4236
- 学会 / 主办单位
- ChAbS
- 官网最新一期
- Volume 9, Issue 3(2026 年 7 月)
- 官方链接
- 期刊主页 ↗LetPub
- 投稿系统 ↗出版商官网
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
- 查重政策 ↗DOAJ
常见问题
关于 Antibody Therapeutics 的常见问题
Antibody Therapeutics 是中科院几区期刊?
2026 年新锐版分区表中为医学 3区。不同版本与大小类分区不能混用。
Antibody Therapeutics 的影响因子是多少?
期刊官网公布的影响因子为 56(2025 年度),属期刊自述数据,LetPub 暂无该刊的影响因子记录,CiteScore 为 7.8,h-index 为 34。
Antibody Therapeutics 的审稿周期多长?
按 2024年10月至2026年10月(近 24 个月)73 篇已发表文章登记的日期,投稿到接收的中位数为 103 天(四分位 69–134 天);投稿社区反馈的平均审稿速度为约 8 周。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。
Antibody Therapeutics 的投稿格式要求是什么?
据期刊作者指南:摘要:≤ 250 词;关键词:≥ 3 个;正文篇幅:≤ 5,000 词;参考文献格式:顺序编码制(按引用顺序编号);首次投稿格式:允许不按期刊格式排版(free format)。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。
Antibody Therapeutics 的编委会里有中国学者吗?
期刊官网编委会页面上标注了国家的 37 位编委中,中国大陆 17 位(约 46%);人数最多的国家是 中国(17 位)、美国(16 位)、英国(1 位)。统计按编委会页面列出的机构国家计,仅供参考。
Antibody Therapeutics 被哪些数据库收录?
据 LetPub 与 DOAJ 记录,Antibody Therapeutics 被 ESCI、Scopus、DOAJ 收录。
Antibody Therapeutics 是开放获取期刊吗?版面费多少?
Antibody Therapeutics 为完全开放获取。APC 约 2,687 美元。
来源与更新
本页事实来自 LetPub、OpenAlex、DOAJ、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。